Thomas DeLeon

792 total citations
19 papers, 526 citations indexed

About

Thomas DeLeon is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Thomas DeLeon has authored 19 papers receiving a total of 526 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in Thomas DeLeon's work include Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Thomas DeLeon is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Thomas DeLeon collaborates with scholars based in United States and Brazil. Thomas DeLeon's co-authors include Mitesh J. Borad, Daniel H. Ahn, Ahmad H. Ali, Mohamad Bassam Sonbol, Raquel T. Yokoda, Alan H. Bryce, Bashar Aqel, Tanios Bekaii‐Saab, Marcela Salomao and Amit K. Mathur and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Hepatology.

In The Last Decade

Thomas DeLeon

19 papers receiving 519 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas DeLeon United States 10 244 237 166 123 116 19 526
Ryuta Nishitai Japan 13 174 0.7× 341 1.4× 134 0.8× 87 0.7× 52 0.4× 42 507
Hueseyin Bektas Germany 11 162 0.7× 326 1.4× 184 1.1× 102 0.8× 112 1.0× 21 609
Howard M. Karpoff United States 9 231 0.9× 123 0.5× 107 0.6× 75 0.6× 117 1.0× 13 431
Keiichi Kubota Japan 13 210 0.9× 415 1.8× 202 1.2× 64 0.5× 110 0.9× 27 563
Young Hwa Chung South Korea 9 145 0.6× 180 0.8× 287 1.7× 98 0.8× 52 0.4× 14 530
T. T. Wu United States 11 138 0.6× 235 1.0× 61 0.4× 102 0.8× 292 2.5× 13 596
Korinna Leder Germany 11 175 0.7× 124 0.5× 80 0.5× 139 1.1× 44 0.4× 13 531
Cristina B. Geltzeiler United States 10 174 0.7× 275 1.2× 55 0.3× 64 0.5× 49 0.4× 15 503
Entezam Sahovic United States 12 165 0.7× 86 0.4× 74 0.4× 157 1.3× 89 0.8× 30 613
Shu Shen China 14 101 0.4× 268 1.1× 146 0.9× 112 0.9× 163 1.4× 47 542

Countries citing papers authored by Thomas DeLeon

Since Specialization
Citations

This map shows the geographic impact of Thomas DeLeon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas DeLeon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas DeLeon more than expected).

Fields of papers citing papers by Thomas DeLeon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas DeLeon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas DeLeon. The network helps show where Thomas DeLeon may publish in the future.

Co-authorship network of co-authors of Thomas DeLeon

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas DeLeon. A scholar is included among the top collaborators of Thomas DeLeon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas DeLeon. Thomas DeLeon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Ahn, Daniel H., Pedro Luiz Serrano Usón, Peter Masci, et al.. (2021). A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. Investigational New Drugs. 40(1). 134–141. 23 indexed citations
2.
DeLeon, Thomas, Daniel Almquist, Benjamin R. Kipp, et al.. (2020). Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. PLoS ONE. 15(3). e0230306–e0230306. 23 indexed citations
3.
Sonbol, Mohamad Bassam, Tania Jain, Belal Firwana, et al.. (2019). Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis. BMJ Supportive & Palliative Care. 9(4). 425–433. 36 indexed citations
4.
Yokoda, Raquel T., Bolni Marius Nagalo, Jan B. Egan, et al.. (2018). Oncolytic virotherapy in upper gastrointestinal tract cancers. PubMed. Volume 7. 13–24. 13 indexed citations
5.
Parker, David M., et al.. (2018). Genomic Profiling Reveals Medullary Thyroid Cancer Misdiagnosed as Lung Cancer. Case Reports in Oncology. 11(2). 399–403. 1 indexed citations
6.
DeLeon, Thomas, Yumei Zhou, Bolni Marius Nagalo, et al.. (2018). Novel Immunotherapy Strategies for Hepatobiliary Cancers. Immunotherapy. 10(12). 1077–1091. 5 indexed citations
7.
DeLeon, Thomas, Marcela Salomao, Bashar Aqel, et al.. (2018). Pilot evaluation of PD-1 inhibition in metastatic cancer patients with liver transplantations (LT): The Mayo Clinic experience.. Journal of Clinical Oncology. 36(4_suppl). 328–328. 3 indexed citations
8.
Jain, Apurva, Mitesh J. Borad, Robin Kate Kelley, et al.. (2018). Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. JCO Precision Oncology. 2(2). 1–12. 123 indexed citations
9.
Bogenberger, James M., et al.. (2018). Emerging role of precision medicine in biliary tract cancers. npj Precision Oncology. 2(1). 21–21. 23 indexed citations
10.
DeLeon, Thomas, Marcela Salomao, Bashar Aqel, et al.. (2018). Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. Journal of Gastrointestinal Oncology. 9(6). 1054–1062. 116 indexed citations
11.
DeLeon, Thomas, Steven R. Alberts, Robert R. McWilliams, et al.. (2018). A pilot study of ponatinib in cholangiocarcinoma patients with FGFR2 fusions.. Journal of Clinical Oncology. 36(4_suppl). TPS532–TPS532. 2 indexed citations
12.
DeLeon, Thomas, Daniel H. Ahn, James M. Bogenberger, et al.. (2018). Novel Targeted Therapy Strategies for Biliary Tract Cancers and Hepatocellular Carcinoma. Future Oncology. 14(6). 553–566. 16 indexed citations
13.
14.
Yokoda, Raquel T., Bolni Marius Nagalo, Brent L. Vernon, et al.. (2017). Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. PubMed. Volume 6. 39–49. 36 indexed citations
15.
Ali, Ahmad H., James H. Tabibian, Navine Nasser‐Ghodsi, et al.. (2017). Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. Hepatology. 67(6). 2338–2351. 82 indexed citations
16.
DeLeon, Thomas, Benjamin R. Kipp, Blake Langlais, et al.. (2017). Assessment of treatment response to immunotherapy in melanoma patients with pathogenic mutations of NRAS, BRAF, CDKN2A and P53.. Journal of Clinical Oncology. 35(15_suppl). e21057–e21057. 1 indexed citations
17.
DeLeon, Thomas, Mitesh J. Borad, Teresa Wu, et al.. (2017). Utility of CT texture for identification of FGFR2 fusion in cholangiocarcinoma: A radiogenomic pilot study.. Journal of Clinical Oncology. 35(15_suppl). e15626–e15626. 2 indexed citations
18.
DeLeon, Thomas, et al.. (2014). Mycobacterium avium complex empyema in a patient with interferon gamma autoantibodies.. PubMed. 73(9 Suppl 1). 15–7. 5 indexed citations
19.
Elliott, Doug, et al.. (1994). Development and implementation of an instrument measuring CNCs' activities.. PubMed. 10(1). 26–34. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ryuta Nishitai Breakdown of academic impact, for papers by Hueseyin Bektas Breakdown of academic impact, for papers by Howard M. Karpoff Breakdown of academic impact, for papers by Keiichi Kubota Breakdown of academic impact, for papers by Young Hwa Chung Breakdown of academic impact, for papers by T. T. Wu Breakdown of academic impact, for papers by Korinna Leder Breakdown of academic impact, for papers by Cristina B. Geltzeiler Breakdown of academic impact, for papers by Entezam Sahovic Breakdown of academic impact, for papers by Shu Shen
Rankless by CCL
2026